Cargando…

Possible medication error risks with nirmatrelvir+ritonavir

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	News Item
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758346/ http://dx.doi.org/10.1007/s40278-022-08682-z

Ejemplares similares

ISMP releases Top 10 list of medication errors and hazards in 2020
Publicado: (2021)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

ISMP reports: errors or hazards with COVID-19 vaccines
Publicado: (2021)

COVID-19 vaccination errors in USA reported to ISMP
Publicado: (2021)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021
Publicado: (2022)

Possibility of mix-up with paediatric COVID-19 vaccines
Publicado: (2021)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
por: DeMarco, Elizabeth, et al.
Publicado: (2023)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

A New Medical and Surgical Directory of the United States
Publicado: (1885)

Global operation targets rise in counterfeit COVID-related medical items
Publicado: (2020)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

COVID-19 vaccination and risk of neuralgic amyotrophy
Publicado: (2022)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

Hydroxychloroquine: risk of QT prolongation and drug interactions
Publicado: (2020)

Tozinameran vaccination in Canada: no change in benefit-risk profile
Publicado: (2021)

Warnings of risks associated with ivermectin use for COVID-19
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

PRAC updates risk of myocarditis and pericarditis with mRNA vaccines
Publicado: (2021)

Merck says molnupiravir has favourable benefit-risk assessment
Publicado: (2021)

EMA guidance on risk management plans for COVID-19 vaccines reviewed
Publicado: (2020)

No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
Publicado: (2021)

Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
Publicado: (2021)

AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
Publicado: (2021)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
por: Congdon, Seth, et al.
Publicado: (2023)

532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients
por: Leister-Tebbe, Heidi, et al.
Publicado: (2023)

511. Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19
por: Bhargava, Ashish, et al.
Publicado: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6gvncupg83cmvpcn7j2joaefa1